References
- Maidment I, Fox C, Livingston G, Katona K. Drug treatment for Alzheimer’s disease: the way forward. Int. J. Geriatr. Psychiatry21, 6–8 (2006).
- Schneider L. The post-modern world of Alzheimer’s disease trials: how much is an ADAS-cog point worth in central London? Int. J. Geriatr. Psychiatry21, 9–13 (2006).
- Kwon M, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis.3, 148–186 (2006).
- Iliffe S. NICE and drug treatment for Alzheimer’s disease. CNS Drugs21(3), 177–184 (2007).
- Chalkidou K, Hoy A, Littlejohns P. Making a decision to wait for more evidence: when the National Institute for Health & Clinical Excellence recommends a technology only in the context of research. J. R. Soc. Med.100, 453–460 (2007).
- Rawlins M. In pursuit of quality: the National Institute for Clinical Excellence. Lancet353, 1079–1082 (1999).
- Pearson S, Rawlins M. Quality, innovation and value for money: NICE and the British National Health Service. JAMA294, 2618–2622 (2005).
- Williams I, Bryan S, McIver S. How should cost–effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J. Health Serv. Res. Policy12(2), 73–79 (2007).
- Bryan S, Williams I, McIver S. Seeing the NICE side of cost–effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Econ.16, 179–193 (2007).
- Davies E, Littlejohns P. Views of Directors of Public Health about NICE appraisal guidance: results of a postal survey. J. Public Health Med.24(4), 319–325 (2002).
- Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England & Wales. Pharmacoeconomics21(3), 149–157 (2003).
- Walker S, Palmer S, Sculpher M. The role of NICE technology appraisal in NHS rationing. Br. Med. Bull.81–82, 51–64 (2007).
- Pearson S, Littlejohns P. Re-allocating resources: how should the National Institute for Health & Clinical Excellence guide disinvestment efforts in the National Health service? J. Health Serv. Res. Policy12(3), 160–165 (2007).
- Devlin N, Appleby J, Parkin D. Patients views of explicit rationing: what are the implications for health service decision-making? J. Health Serv. Res. Policy8(3), 183–186 (2003).
- Quigley M. A NICE fallacy. J. Med. Ethics33, 465–466 (2007).
- Michaels J. Improving NICE’s social value judgements. Br. Med. J.332, 48–50 (2006).
- Milewa T. Health technology adoption and the politics of governance in the UK. Soc. Sci. Med.63(12), 3102–3112 (2006).
- Taylor R. Using health outcomes data to inform decision-making: government agency perspective. Pharmacoeconomics19(S2), 33–38 (2001).
- Walley T. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing? CNS Drugs18(1), 1–12 (2004).
- Rafferty J. Review of NICE’s recommendations 1999–2005. Br. Med. J.332, 1266–1268 (2006).